Progress, Potential, and Possibilities Podcast / Show

Ira Pastor

Interviews and Discussions With Fascinating People Who are Creating A Better Tomorrow For All Of Us - Host - Ira S. Pastor

  1. APR 9

    The Blood Test That Could Detect Alzheimer’s Years Before Symptoms | Mike Banville - CEO, ALZpath

    Send us Fan Mail What if a simple blood test could detect Alzheimer’s years—maybe even decades—before symptoms ever appear? Mike Banville is the Chief Executive Officer of ALZpath ( https://alzpath.bio/ ), a company at the forefront of transforming how Alzheimer’s disease is detected and monitored through cutting-edge blood-based diagnostics. Mike is a seasoned global executive with a track record of scaling businesses, driving operational transformation, and executing strategic growth through both organic expansion and acquisitions. Prior to ALZpath, he served as CEO of SSB - doubling revenue and shifting the business to a predominantly recurring revenue model. Earlier in his career, Mike spent over two decades at IHS Markit, where he held multiple senior leadership roles across strategy, sales, marketing, and global operations. There, he helped scale the Telecommunications, Media, and Technology division through acquisitions and product integration, while also leading global offshoring strategy and climate-focused market development initiatives. Mike has also led and turned around companies in digital health and athlete development, bringing a consistent focus on data, analytics, and scalable platforms. Now at ALZpath, Mike is applying that same operational and strategic expertise to one of the most urgent challenges in medicine - enabling earlier, more accessible detection of Alzheimer’s disease through innovative biomarker technologies, like pTau217, helping accelerate research, improve clinical care, and ultimately impact millions of patients worldwide. #Alzheimers #AlzheimersDisease #Dementia #BrainHealth #Longevity #Biotech #HealthcareInnovation #Diagnostics #BloodTest #EarlyDetection #Neuroscience #Neurodegeneration #PrecisionMedicine #FutureOfMedicine #MedTech #Biomarkers #TauProtein #pTau217 #StartupCEO #BiotechCEO #HealthcarePodcast #MedicalBreakthrough #AgingResearch #CognitiveHealth #LifeSciences Support the show

    35 min

  2. APR 9

    How Microbiome Data is Transforming Veterinary Medicine | Dr. Bushra Schuitemaker, Ph.D. - Head of Microbiology, Pooch & Mutt - Head of Science and Research, BIOME9

    Send us Fan Mail There’s a revolution happening in pet health right now - where a simple stool sample can reveal disease risk, immune health, and even how long your dog might live. Dr. Bushra Schuitemaker, Ph.D. is a microbiologist, zoologist, and science leader working at the cutting edge of microbiome research, animal health, and nutrition.  Dr. Schuitemaker serves as Head of Science and Research at BIOME9 ( https://biome9.com/ ), a leading platform for canine gut microbiome analysis, and Head of Microbiology at Pooch & Mutt ( https://www.poochandmutt.co.uk/ ), where she helps translate microbiome science into real-world products and interventions for pet health. Dr. Schuitemaker’s work sits at the intersection of microbial ecology, bioinformatics, and machine learning, where she develops tools to decode the gut microbiome and turn complex data into actionable insights for veterinarians, pet owners, and the pet food industry. Her expertise spans metagenomics, metabolomics, and multi-omics integration, with a focus on identifying biomarkers that can drive precision health approaches in animals. Dr. Schuitemaker completed her Ph.D. in Zoology at the University of East Anglia, where she pioneered microbiome-based biomarkers of poultry gut health, and has also contributed to human health research, including microbiome and metabolomics studies in childhood obesity. A passionate advocate for “One Medicine” - the idea that human and animal health are deeply interconnected - Dr. Schuitemaker is also an active science communicator, collaborating across academia, industry, and policy to make microbiome science more impactful, inclusive, and accessible. #Microbiome #DogHealth #GutHealth #CanineMicrobiome #PetHealth #DogLongevity #VeterinaryScience #OneMedicine #OneHealth #PrecisionNutrition #Bioinformatics #MachineLearning #AnimalHealth #PetCare #DogsOfYouTube #DogWellness #HealthScience #FutureOfMedicine #LongevityScience #Metagenomics #Biome9 #PoochAndMutt #SciencePodcast #Biotech #AgingResearch Support the show

    52 min

  3. APR 7

    Breaking Stigma Around Digestive Health Issues - Eric Foster - Chief Commercial Officer, Ardelyx

    Send us Fan Mail What if the biggest barrier in healthcare today isn’t science - but stigma? Eric Foster is Chief Commercial Officer at Ardelyx ( https://ardelyx.com/ ), a biopharmaceutical company where he leads global commercialization strategy for innovative therapies addressing high-burden gastrointestinal and cardiorenal diseases.  A seasoned biotech executive with over two decades of experience, Eric has built and scaled high-performing commercial organizations across some of the industry’s most complex and competitive markets. Prior to Ardelyx, Eric held senior leadership roles at Amgen and Horizon Therapeutics, where he led rare disease and specialty business units, overseeing product launches, market access, and global growth strategy. Earlier in his career, he spent over a decade at GSK and began in commercial roles at Johnson & Johnson. Eric is known for his expertise in rare disease commercialization, payer strategy, and building first-in-class market entry plans, with a strong focus on connecting patients to therapies and reducing barriers to care. He holds an MBA in Healthcare from Auburn University and a BA in Economics from the University of Georgia. #IBSC #GutHealth #WomensHealth #HealthcareInnovation #Biotech #PharmaMarketing #LPGA #WomensSports #DigitalHealth #PatientAwareness #ChronicIllness #HealthEducation #MedicalInnovation #HealthcareMarketing #BehaviorChange #HealthStigma #ChronicDisease #Biopharma #HealthPodcast #FutureOfHealthcare Support the show

    28 min

  4. APR 7

    From Lab to Clinic: The Science Behind Exosome Therapy for Paralysis | Dr. Lior Shaltiel - Chief Executive Officer, NurExone Biologic

    Send us Fan Mail What if paralysis wasn’t permanent—but just a biological system we haven’t figured out how to reboot? Dr. Lior Shaltiel, Ph.D. is Chief Executive Officer of NurExone Biologic ( https://nurexone.com/ ), a biotech company pioneering a novel exosome-based platform aimed at repairing the central nervous system. Dr. Shaltiel brings a rare combination of deep scientific training and cross-border biotech leadership. He earned his Ph.D. in molecular pharmacology from Ludwig Maximilian University of Munich, where his research focused on ion channels and retinal biology - early work that connects directly to today’s frontier in neuroregeneration. Before stepping into the CEO role, Dr. Shaltiel led R&D programs in advanced drug delivery systems, including liposome-based therapeutics, and worked in global biotech investment and partnerships. He’s also the founder of the BioMed MBA program at Hebrew University of Jerusalem, helping train the next generation of biotech leaders. At NurExone, Dr. Shaltiel is advancing the company’s ExoTherapy platform - leveraging extracellular vesicles to deliver targeted genetic payloads. Their lead program, ExoPTEN, is an intranasal exosome therapy designed to silence the PTEN gene and promote neuronal regeneration after spinal cord injury - an area where, to date, there are no approved treatments that restore lost function. #biotech #neuroscience #spinalcordinjury #regenerativemedicine #exosomes #stemcells #futureofmedicine #geneediting #biotechinnovation #medicalbreakthrough #neuroregeneration #sciencepodcast #healthtech #longevity #drugdiscovery #PTEN #RNAi #nextgenmedicine #biophysics #medtech Support the show

    36 min

  5. APR 7

    Rethinking Aging In Dogs: Function, Mobility And The Future of Longevity | Dr. Laurie McCauley, DVM - Founder and Instructional Director, Optimum Pet Vitality

    Send us Fan Mail What if most dogs aren’t dying of old age - but from losing their ability to move? Dr. Laurie McCauley, DVM, DACVSMR, CCRT, CVA, CVC is a pioneer in veterinary rehabilitation and one of the most influential figures in canine sports medicine. With over two decades at the forefront of the field, she founded the first dedicated veterinary rehabilitation clinic in the United States and designed the world’s first underwater treadmill specifically for dogs - innovations that helped transform how veterinarians approach mobility, recovery, and performance in animals. A board-certified specialist in Canine Sports Medicine and Rehabilitation, Dr. McCauley has trained thousands of veterinarians, physical therapists, and rehabilitation professionals around the world, and her work has played a central role in shaping modern standards of care. Dr. McCauley is the founder and instructional director of Optimum Pet Vitality ( https://optimumpetvitality.com/ ), an education platform focused on delivering evidence-based, practical training to veterinary professionals and pet owners alike, covering areas such as therapeutic exercise, laser therapy, and fascia-based treatments. In addition, Dr. McCauley is the owner of Red Tail Rehab, where she provides personalized, in-home rehabilitation care, helping animals improve mobility, reduce pain, and enhance quality of life. Dr. McCauley’s career has been defined by a singular mission: to help animals move better, feel better, and ultimately live longer, healthier lives. #DogLongevity #PetHealth #CanineRehab #DogAging #VeterinaryMedicine #PetWellness #HealthyPets #DogHealth #LongevityScience #AnimalHealth #PetCareTips #SeniorDogs #CanineHealth #MobilityMatters #PetLongevity #VeterinaryRehabilitation #DogFitness #AgingResearch #BiohackingPets #Healthspan Support the show

    53 min

  6. APR 7

    Optogenetics, Biohybrid Implants And The Future Of Brain-Computer Interfaces | Dr. Alan Mardinly, Ph.D. - Chief Scientific Officer and Co-Founder, Science Corp.

    Send us Fan Mail What if we could restore vision, communicate directly with the brain, and even extend human life—not with machines alone, but with living, engineered biology? Dr. Alan Mardinly, Ph.D. is the Chief Scientific Officer and Co-Founder of Science Corp. ( https://science.xyz/ ), a neurotechnology company developing next-generation brain interfaces and biohybrid neural implants aimed at restoring human function. Dr. Mardinly leads the company’s biohybrid program, focused on combining genetically engineered cells with advanced optical hardware to create optogenetic therapies for vision restoration and new types of brain-machine interfaces. Dr. Mardinly has spent more than 15 years working at the intersection of neuroscience, genetics, and neural engineering.  Dr. Mardinly earned his PhD in Neurobiology from Harvard University, where his research explored how experience and activity-dependent gene programs shape synaptic plasticity in inhibitory neurons—work that helped illuminate how neural circuits maintain stability while adapting to learning and sensory experience. Following Harvard, Dr. Mardinly conducted postdoctoral research at UC Berkeley, where he helped pioneer holographic optogenetics, a technology capable of stimulating specific neurons with extraordinary spatial and temporal precision. Dr. Mardinly later joined Neuralink, where he served as Director of Biology, leading teams focused on advancing brain-machine interface technologies.  In 2021, Dr. Mardinly co-founded Science Corp., where he now works to translate cutting-edge neuroscience into therapeutic systems designed to restore vision and build the next generation of neural interfaces. #Neurotechnology  #BrainComputerInterface #Optogenetics #VisionRestoration #Biohybrid #ScienceCorp #Neuralink #FutureOfMedicine #BrainImplants #ArtificialVision #Neuroscience #Biotech #Longevity #LifeSupport #SyntheticBiology #HumanAugmentation #NextGenMedicine #DeepTech #Innovation #FutureOfHealthcare Support the show

    51 min

  7. APR 6

    A New Path Forward For Rare Disease Treatments - Craig Martin - CEO - Orphan Therapeutics Accelerator

    Send us Fan Mail There are over 9,000 rare diseases affecting 300 million people—and yet 90% of them have no approved treatment. Why? Craig Martin is the Founder and CEO of Orphan Therapeutics Accelerator ( https://www.orphantxl.com/ ), a pioneering nonprofit launched in 2024 to advance shelved therapies for ultra-rare diseases—bringing overlooked science back to life and guiding it through approval and into patients’ hands through innovative development and commercialization pathways. With more than two decades at the intersection of biotech, digital health, and healthcare strategy, Craig has built a career around unlocking value in overlooked opportunities and tackling some of medicine’s toughest challenges. He previously founded Rithm Health, where he has advised emerging biotech and health technology companies on strategy, growth, and stakeholder engagement. Craig also served as CEO of Global Genes, one of the world’s leading rare disease patient advocacy organizations, where he reversed declining revenues, launched major new initiatives, and led a successful merger with RARE-X—expanding the organization’s impact across the rare disease ecosystem. Earlier in his career, Craig spent over a decade leading Ogilvy | Feinstein Kean Healthcare, and held leadership roles at Ogilvy Consulting and Ruder Finn, advising global pharma, biotech, and health innovators. A graduate of Duke University, Craig brings a unique blend of strategic insight, policy awareness, and deep commitment to patients—focused on transforming how therapies for ultra-rare diseases are developed, financed, and delivered. #RareDisease #UltraRareDisease #Biotech #HealthcareInnovation #DrugDevelopment #GeneTherapy #OrphanDrugs #Pharma #MedicalInnovation #FutureOfMedicine #HealthTech #LifeSciences #BiotechInnovation #DrugDiscovery #PatientAccess #Healthcare #Medicine #Science #Innovation #NonprofitBiotech #RareDiseaseAwareness #GlobalHealth Support the show

    40 min

  8. APR 4

    The Breakthroughs Bringing Fusion Power to the Grid - Daniel Clark - Director of Nuclear and Fuel Cycle Engineering, Type One Energy Group

    Send us Fan Mail Inside a fusion reactor, you’re not just creating a star—you’re building a machine that has to survive one. Temperatures hotter than the sun, relentless neutron bombardment… and materials that slowly destroy themselves from the inside out. Daniel Clark is a nuclear engineer and fusion energy expert working at the forefront of turning fusion from a scientific pursuit into a practical energy solution. Daniel is currently Director of Nuclear and Fuel Cycle Engineering at Type One Energy Group ( https://typeoneenergy.com/ ), where he leads critical efforts in breeder blanket and first wall design, as well as the tritium fuel cycle - core systems that will ultimately determine whether fusion reactors can operate sustainably at scale. Prior to joining the private sector, Daniel spent nearly eight years at the U.S. Department of Energy Office of Science, where he managed the Fusion Materials Research Portfolio. During that time, he helped launch major national initiatives, including the Material Plasma Exposure eXperiment at Oak Ridge National Laboratory, the INFUSE public-private partnership program, and the Fusion Prototypic Neutron Source. With degrees in nuclear engineering from Texas A&M University and University of Tennessee, Knoxville, Daniel brings a rare combination of deep technical expertise, federal policy insight, and commercialization experience—making him one of the key voices shaping the future of fusion energy. #FusionEnergy #NuclearFusion #CleanEnergy #FutureOfEnergy #EnergyInnovation #DeepTech #ClimateTech #Physics #NuclearEngineering #MaterialsScience #EnergyTransition #Tritium #SciencePodcast #TechPodcast #HardTech #Engineering #Innovation #FusionPower #StartupEnergy #BigScience #NextGenEnergy #AdvancedMaterials #EnergyFuture #BreakthroughScience #ClimateSolutions Support the show

    46 min
See All (818)

Ratings & Reviews

5
out of 5
6 Ratings

About

Interviews and Discussions With Fascinating People Who are Creating A Better Tomorrow For All Of Us - Host - Ira S. Pastor

Information

You Might Also Like